Synergistic anticancer effects of cisplatin and histone deacetylase inhibitors (SAHA and TSA) on cholangiocarcinoma cell lines
- 9 November 2015
- journal article
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 48 (1) , 409-420
Abstract
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publicationsKeywords
This publication has 34 references indexed in Scilit:
- Histone deacetylase (HDAC) inhibitory and antiproliferative activities of phenolic-rich extracts derived from the rhizome of Hydnophytum formicarum Jack.: sinapinic acid acts as HDAC inhibitorBMC Complementary and Alternative Medicine, 2013
- Anticancer effects of suberoylanilide hydroxamic acid in esophageal squamous cancer cellsin vitroandin vivoDiseases of the Esophagus, 2013
- Molecular Mechanism of SAHA on Regulation of Autophagic Cell Death in Tamoxifen-Resistant MCF-7 Breast Cancer CellsInternational Journal of Medical Sciences, 2012
- Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptideBritish Journal of Cancer, 2011
- Molecular Pathogenesis of CholangiocarcinomaInternational Journal of Hepatology, 2011
- The Histone Deacetylase Inhibitor Trichostatin A Synergistically Resensitizes a Cisplatin Resistant Human Bladder Cancer Cell LineJournal of Urology, 2011
- Preclinical Studies of Chemotherapy Using Histone Deacetylase Inhibitors in Endometrial CancerObstetrics and Gynecology International, 2010
- Effectiveness of Trichostatin A as a Potential Candidate for Anticancer Therapy in Non–Small-Cell Lung CancerThe Annals of Thoracic Surgery, 2006
- Histone deacetylase inhibitors and cancer: from cell biology to the clinicEuropean Journal of Cell Biology, 2005
- Cisplatin: mode of cytotoxic action and molecular basis of resistanceOncogene, 2003